In terms of molecular targeting approaches to breast cancer, targeting Her2, a tyrosine receptor kinase, has been widely used in a relatively successful manner for Her2-positive breast cancer [2,3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.